DE69433831D1 - Modifizierung von Pertussistoxin - Google Patents

Modifizierung von Pertussistoxin

Info

Publication number
DE69433831D1
DE69433831D1 DE69433831T DE69433831T DE69433831D1 DE 69433831 D1 DE69433831 D1 DE 69433831D1 DE 69433831 T DE69433831 T DE 69433831T DE 69433831 T DE69433831 T DE 69433831T DE 69433831 D1 DE69433831 D1 DE 69433831D1
Authority
DE
Germany
Prior art keywords
modification
pertussis toxin
pertussis
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69433831T
Other languages
English (en)
Other versions
DE69433831T2 (de
Inventor
Glen D Armstrong
Randy J Read
Raymond Oomen
Bart Hazes
Penelope E Stein
Sheena Loosmore
Stephen A Cockle
Michel H Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Sanofi Pasteur Ltd
Original Assignee
University of Alberta
Aventis Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta, Aventis Pasteur Ltd filed Critical University of Alberta
Publication of DE69433831D1 publication Critical patent/DE69433831D1/de
Application granted granted Critical
Publication of DE69433831T2 publication Critical patent/DE69433831T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69433831T 1993-08-24 1994-08-23 Modifizierung von Pertussistoxin Expired - Fee Related DE69433831T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11094793A 1993-08-24 1993-08-24
US110947 1993-08-24
US25112194A 1994-05-31 1994-05-31
US251121 1994-05-31

Publications (2)

Publication Number Publication Date
DE69433831D1 true DE69433831D1 (de) 2004-07-15
DE69433831T2 DE69433831T2 (de) 2005-06-23

Family

ID=26808533

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433831T Expired - Fee Related DE69433831T2 (de) 1993-08-24 1994-08-23 Modifizierung von Pertussistoxin

Country Status (3)

Country Link
US (5) US5856122A (de)
EP (1) EP0646599B1 (de)
DE (1) DE69433831T2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169724T3 (es) * 1992-10-02 2002-07-16 Alberta Res Council Propiedades antiinflamatorias, tolerogenicas e inmunoestimulantes de peptidos que enlazan carbohidratos.
US5856122A (en) * 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
DE19543569C2 (de) * 1995-11-22 1998-01-22 Atou Lo Verwendung des Lectins Sambucus nigra zur Quantifizierung der endständigen Sialinsäurereste des Human-Transferrin-Moleküls mittels einer vollimmunoenzymatischen Methode (EIA)
CA2244228A1 (en) 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6842704B2 (en) 1998-02-04 2005-01-11 Immunex Corporation Crystalline TNF-α-converting enzyme and uses thereof
JP2003506411A (ja) * 1999-08-09 2003-02-18 トリペップ アクチ ボラゲット タンパク質重合阻害剤および使用方法
US7135173B2 (en) * 2000-07-13 2006-11-14 Idaho Research Foundation, Inc. Antiviral activity of Shiga toxin
US6541013B1 (en) 2000-07-13 2003-04-01 Idaho Research Foundation, Inc. Methods and compositions for suppressing bovine leukemia virus with a Shiga toxin polypeptide
EP1351982B1 (de) 2000-12-09 2008-02-13 The Regents Of The University Of California Röntgenkristallstruktur mit 5.5 a auflösung von funktionalen komplexen des bakteriellen ribosoms, beinhaltend transfer-rna und modell boten-rna
WO2003024995A1 (en) * 2001-09-19 2003-03-27 Tripep Ab Molecules that block viral infectivity and methods of use thereof
US8032347B2 (en) * 2001-11-01 2011-10-04 The University Of British Columbia Methods and apparatus for protein sequence analysis
US20040180893A1 (en) * 2003-02-21 2004-09-16 Balzarini Jan Maria Rene Identification of compounds that inhibit replication of human immunodeficiency virus
US20050096319A1 (en) * 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
KR101337320B1 (ko) * 2003-11-20 2013-12-06 사노피 파스퇴르 인크 백일해 독소의 정제방법 및 이에 유용한 펩타이드
WO2008154456A2 (en) * 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
PL404247A1 (pl) 2013-06-07 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP7059776B2 (ja) 2018-04-24 2022-04-26 株式会社デンソー 並列化方法、並列化ツール、及びマルチコアマイコン

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US4883761A (en) * 1986-03-25 1989-11-28 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
IT1223529B (it) * 1987-12-18 1990-09-19 Sclavo Spa Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse
AU631351B2 (en) * 1988-04-20 1992-11-26 Massachusetts Health Research Institute, Inc. (Mhri) Pertussis toxoid vaccine
IT1229766B (it) * 1989-05-19 1991-09-10 Sclavo Spa Peptidi sintetici capaci di stimolare una immunita' t cellulare.
JPH05503628A (ja) * 1989-11-29 1993-06-17 スミスクライン　ビーチヤム　バイオロジカルズ（エス　ア） 新規なワクチン
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
IL101692A0 (en) * 1991-05-03 1992-12-30 Amgen Inc Recombinant b oligomer of pertussis toxin
US5817617A (en) * 1991-05-03 1998-10-06 The Rockefeller University Selectin and pertussis toxin derived peptides and uses thereof
US5856122A (en) * 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin

Also Published As

Publication number Publication date
EP0646599A3 (de) 1996-05-15
US5856122A (en) 1999-01-05
EP0646599B1 (de) 2004-06-09
US5977304A (en) 1999-11-02
US6018022A (en) 2000-01-25
US6168928B1 (en) 2001-01-02
DE69433831T2 (de) 2005-06-23
US5965385A (en) 1999-10-12
EP0646599A2 (de) 1995-04-05

Similar Documents

Publication Publication Date Title
DE69433831D1 (de) Modifizierung von Pertussistoxin
DE69431458D1 (de) Echtheitsüberprüfung von Gegenständen
NO943763D0 (no) 4-arylamino-benzopyraner og beslektede forbindelser
DE69319679D1 (de) Eingabe von Sonderbuchstaben
DE59403737D1 (de) Drehkreuz
DE69421273D1 (de) Kristallisation von 2,6-dimethylnaphthalin
KR950001480U (ko) 문틀
FI941146A (fi) Iskulaite
DK36193D0 (da) Fremgangsmaade
NO930418D0 (no) Innstikkbar helletut
DE69417915D1 (de) Reinigung von uranhexafluorid
KR950019182U (ko) 문틀
KR950011841U (ko) 문틀
KR950013629U (ko) 제함기의 제함장치
DK87993D0 (da) Fremgangsmaade
DK143793D0 (da) Fremgangsmaade
DK119993D0 (da) Fremgangsmaade
KR950008165U (ko) 지압구
KR940025004U (ko) 급속 개폐식 문
DE69325271D1 (de) Hydrosilylierung von fullarenen
ATA19993A (de) Krücke
KR940021028U (ko) 제습기의 만수방지장치
KR950001459U (ko) 솔레노이드
FI787U1 (fi) Resultatblankett foer oevnings- och provskjutning
DE59403046D1 (de) Glycosylamide von 2-aminoacylamino-2-desoxy-zuckern

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee